Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine

International Journal of Oncology

Volumn 14, Issue 5, 1999, Pages 945-950

  Mohammad, Ramzi M ^a   Limvarapuss, Chainarong ^a   Hamdy, Nayera ^a   Dutcher, Bonni S ^b   Beck, Frances W J ^a   Wall, Nathan R ^a   Al Katib, Ayad M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Genentech Bio Oncology   (United States)

Author keywords

B cell; Bryostatin 1; Chronic lymphocytic leukemia; Fludarabine; SCID mice; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; DRUG DERIVATIVE; FLUDARABINE; LACTONE; MACROLIDE; VIDARABINE;

ANIMAL; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MOUSE; MOUSE MUTANT; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTONES; LEUKEMIA, B-CELL, CHRONIC; MACROLIDES; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0033126464     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.5.945     Document Type: Article

References (27)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998. CA - Cancer J Clin 48: 6-29, 1998.
2. Armitage JO, Berg AR and Purtilo DT: Adult non-Hodgkin's lymphoma. In: Hematology Clinical and Laboratory Practice. Bick RL, Bennett JM, Brynes RK, Cline MJ, Kass L, Mutano G, Shohet SB and Ward PCJ (eds). Vol. 2. C.V. Mosby, Inc., St. Louis, MO, pp875-893, 1993.
3. Kitada S, Anderson J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang H-G, Zhang X, Bullrich F, Croce CM, Rai K, Hines J and Reed JC: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91: 3379-3389, 1998.
4. Reed JC: Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451-473, 1995.
5. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K, Abubakr YA, Dugan MC and Al-Katib A: Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 10: 130-137, 1996.
6. Mohammad RM, Katato K, Almatch VP, Wall N, Liu K-Z, Schltz CP, Mantsch HH, Varterasian M and Al-Katib AM: Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clin Cancer Res 4: 445-453, 1998.
7. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S and Rai KR: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996.
8. Goodman MG, Spinosa JC, Saven A, Piro LD and Wormsley S: New prespective on the approach to chronic lymphocytic leukemia. Leuk Lymphoma 22: 1-10, 1996.
9. Drexler HG, Gignac SM, Jones RA, Scott CS, Pettit GR and Hoffbrand AV: Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 74: 1747-1757, 1989.
10. Al-Katib A, Mohammad RM, Dan M, Hussein ME, Akhtar A, Pettit GR and Sensenbrenner LL: Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 21: 61-65, 1993.
11. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E and Clardy J: Isolation and structure of bryostatin 1. J Am Chem Soc 104: 6846-6848, 1982.
12. Mohammad RM, Al-Katib A, Pettit GR and Sensenbrenner LL: Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk Res 17: 1-8, 1993.
13. Mohammad RM, Al-Katib A, Pettit GR and Sensenbrenner LL: Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 54: 165-168, 1994.
14. Al-Katib A, Smith M, Kamanda W, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B and Mohammad MR: Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4: 1305-1314, 1998.
15. Mohammad RM, Beck FWJ, Katato K, Hamdy N, Wall N and Al-Katib A: Potentiation of 2-Chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2. Biol Chem 379: 80-89, 1998.
16. Phipott NJ, Turner AJC, Scopes J, Westby M, Marsh JCW, Gordon-Smith EC, Dalgleish AG and Gibson FM: The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 87: 2244-2251, 1996.
17. Piro LD, Carrera CJ, Son DA and Beutler E: Lasting remission in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117-1121, 1990.
18. Saven A and Piro LD: Newer purine analogue for the treatment of hairy cell leukemia. N Engl J Med 330: 691-697, 1994.
19. Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman K, Stolt C-M, Evensen SA, Albertioni F, Tjonnfjord G, Leukci R and Liliemark J: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13: 989-995, 1995.
20. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G and Grant S: Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress bcl-2. Mol Pharmacol 52: 1000-1009, 1997.
21. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC and Keating M: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156: 2624-2630, 1996.
22. Reed JC: Dysregulation of apoptosis in non-Hodgkin's lymphoma: toward a molecular understanding of bcl-2. Adv Leuk Lymph 7: 1-15, 1997.
23. Iwassaki H, Huang P, Keating MJ and Plunkett W: Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90: 270-278, 1997.
24. Plunkett W and Gandhi V: Cellular metabolism of nucleoside analogs in CLL: implications for drug development. In: Chronic Lymphocytic Leukemia. Scientific Advances and Clinical Developments. Cheson BD (ed). Marcel Dekker Inc., New York, NY, pp197-219, 1992.
25. Plunkett W, Huang P and Gandhi V: Metabolism and action of fludarabine phosphate. Semin Oncol 17 (Suppl 8): 3-17, 1990.
26. Plunkett W and Saunders PP: Metabolism and action of purine nucleoside analogs. Pharmacol Ther 49: 239-268, 1991.
27. Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W and Andreeff M: Differential induction of apoptosis by fludarabine monophosphate in leukemia B and normal T cells in chronic lymphocytic leukemia. Blood 91: 1742-1748, 1998.